Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia

Kwang Kon Koh, Michael J. Quon, Soo Lim, Yonghee Lee, Ichiro Sakuma, Youn Hee Lee, Seung Hwan Han, Eak Kyun Shin

Research output: Contribution to journalArticleResearchpeer-review

24 Citations (Scopus)

Abstract

Background: We investigated effects of fenofibrate therapy on endothelial dysfunction and adipocytokine profiles. Methods: A randomized, single-blind, placebo-controlled, cross-over study was conducted in 53 patients with primary hypertriglyceridemia. We administered placebo or fenofibrate 160 mg daily for 8 weeks. Results: When compared with placebo, fenofibrate therapy substantially lowered plasma levels of TNF-α by 6 ± 3% (P= 0.014) and hsCRP from 1.10 to 0.90 mg/l (P= 0.004). When compared with placebo, fenofibrate therapy increased plasma levels of adiponectin by 17 ± 4% (P= 0.001), insulin sensitivity by 4 ± 1% (as assessed by QUICKI, P= 0.009), and decreased plasma levels of leptin and resistin by 4 ± 7% (P= 0.022) and 10 ± 3% (P= 0.001), respectively. There were correlations between percent changes in QUICKI and percent changes in adiponectin levels (r= 0.279, P= 0.043) or leptin (r= -0.280, P= 0.042). Conclusions: Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients.

Original languageEnglish
Pages (from-to)144-147
Number of pages4
JournalAtherosclerosis
Volume214
Issue number1
DOIs
StatePublished - 1 Jan 2011

Fingerprint

Fenofibrate
Adipokines
Hypertriglyceridemia
Placebos
Adiponectin
Leptin
Insulin Resistance
Resistin
Therapeutics
Cross-Over Studies
Biomarkers

Keywords

  • Adipocytokines
  • Endothelial function
  • Fenofibrate
  • Hypertriglyceridemia
  • Insulin resistance

Cite this

Koh, Kwang Kon ; Quon, Michael J. ; Lim, Soo ; Lee, Yonghee ; Sakuma, Ichiro ; Lee, Youn Hee ; Han, Seung Hwan ; Shin, Eak Kyun. / Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. In: Atherosclerosis. 2011 ; Vol. 214, No. 1. pp. 144-147.
@article{48aa280d60a44c3e84910cd5226a6790,
title = "Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia",
abstract = "Background: We investigated effects of fenofibrate therapy on endothelial dysfunction and adipocytokine profiles. Methods: A randomized, single-blind, placebo-controlled, cross-over study was conducted in 53 patients with primary hypertriglyceridemia. We administered placebo or fenofibrate 160 mg daily for 8 weeks. Results: When compared with placebo, fenofibrate therapy substantially lowered plasma levels of TNF-α by 6 ± 3{\%} (P= 0.014) and hsCRP from 1.10 to 0.90 mg/l (P= 0.004). When compared with placebo, fenofibrate therapy increased plasma levels of adiponectin by 17 ± 4{\%} (P= 0.001), insulin sensitivity by 4 ± 1{\%} (as assessed by QUICKI, P= 0.009), and decreased plasma levels of leptin and resistin by 4 ± 7{\%} (P= 0.022) and 10 ± 3{\%} (P= 0.001), respectively. There were correlations between percent changes in QUICKI and percent changes in adiponectin levels (r= 0.279, P= 0.043) or leptin (r= -0.280, P= 0.042). Conclusions: Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients.",
keywords = "Adipocytokines, Endothelial function, Fenofibrate, Hypertriglyceridemia, Insulin resistance",
author = "Koh, {Kwang Kon} and Quon, {Michael J.} and Soo Lim and Yonghee Lee and Ichiro Sakuma and Lee, {Youn Hee} and Han, {Seung Hwan} and Shin, {Eak Kyun}",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.atherosclerosis.2010.10.023",
language = "English",
volume = "214",
pages = "144--147",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. / Koh, Kwang Kon; Quon, Michael J.; Lim, Soo; Lee, Yonghee; Sakuma, Ichiro; Lee, Youn Hee; Han, Seung Hwan; Shin, Eak Kyun.

In: Atherosclerosis, Vol. 214, No. 1, 01.01.2011, p. 144-147.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia

AU - Koh, Kwang Kon

AU - Quon, Michael J.

AU - Lim, Soo

AU - Lee, Yonghee

AU - Sakuma, Ichiro

AU - Lee, Youn Hee

AU - Han, Seung Hwan

AU - Shin, Eak Kyun

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background: We investigated effects of fenofibrate therapy on endothelial dysfunction and adipocytokine profiles. Methods: A randomized, single-blind, placebo-controlled, cross-over study was conducted in 53 patients with primary hypertriglyceridemia. We administered placebo or fenofibrate 160 mg daily for 8 weeks. Results: When compared with placebo, fenofibrate therapy substantially lowered plasma levels of TNF-α by 6 ± 3% (P= 0.014) and hsCRP from 1.10 to 0.90 mg/l (P= 0.004). When compared with placebo, fenofibrate therapy increased plasma levels of adiponectin by 17 ± 4% (P= 0.001), insulin sensitivity by 4 ± 1% (as assessed by QUICKI, P= 0.009), and decreased plasma levels of leptin and resistin by 4 ± 7% (P= 0.022) and 10 ± 3% (P= 0.001), respectively. There were correlations between percent changes in QUICKI and percent changes in adiponectin levels (r= 0.279, P= 0.043) or leptin (r= -0.280, P= 0.042). Conclusions: Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients.

AB - Background: We investigated effects of fenofibrate therapy on endothelial dysfunction and adipocytokine profiles. Methods: A randomized, single-blind, placebo-controlled, cross-over study was conducted in 53 patients with primary hypertriglyceridemia. We administered placebo or fenofibrate 160 mg daily for 8 weeks. Results: When compared with placebo, fenofibrate therapy substantially lowered plasma levels of TNF-α by 6 ± 3% (P= 0.014) and hsCRP from 1.10 to 0.90 mg/l (P= 0.004). When compared with placebo, fenofibrate therapy increased plasma levels of adiponectin by 17 ± 4% (P= 0.001), insulin sensitivity by 4 ± 1% (as assessed by QUICKI, P= 0.009), and decreased plasma levels of leptin and resistin by 4 ± 7% (P= 0.022) and 10 ± 3% (P= 0.001), respectively. There were correlations between percent changes in QUICKI and percent changes in adiponectin levels (r= 0.279, P= 0.043) or leptin (r= -0.280, P= 0.042). Conclusions: Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients.

KW - Adipocytokines

KW - Endothelial function

KW - Fenofibrate

KW - Hypertriglyceridemia

KW - Insulin resistance

UR - http://www.scopus.com/inward/record.url?scp=78650828581&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2010.10.023

DO - 10.1016/j.atherosclerosis.2010.10.023

M3 - Article

VL - 214

SP - 144

EP - 147

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -